[From Council on Foreign Relations, July 17, 2018] “Next week, some 15,000 participants from around the world will come together to discuss progress on responding to the HIV epidemic. The 22nd International AIDS Conference is an opportunity to reflect on how far we have come, but also to chart our way forward. This year is a […]
To End the HIV Epidemic, Focus on Sexual Violence Prevention Read More »
[From The New York Times, July 16, 2018] “On July 3, 1981, this newspaper wrote about a “rare cancer” killing gay men in New York and California. Though few knew it, what followed would be a generation-defining battle: for attention, for legitimacy, for our very lives. Today, after 37 years, we finally have a proven pathway
Why Don’t More Americans Use PrEP? Read More »
[From tctMD, July 13, 2018] “People with HIV are more than twice as likely to develop cardiovascular disease than those without the virus, according to the results of a new review and meta-analysis. CVD attributable to HIV has more than doubled globally over the past two decades, from 0.36% in 1990 to 0.92% in 2015,
Global Burden of HIV-Related CVD Has Tripled Over Two Decades Read More »
[From France24, July 12, 2018] “The AIDS Association of France has launched a nationwide campaign to raise awareness of PrEP, an antiviral drug that protects against HIV. Although little known in France, the medication has proven effective in countries like the US and UK.” For more, click here.
PrEP pill to prevent HIV remains little known in France Read More »
[From OttawaCitizen, July 12, 2018] “MISSISSAUGA, Ontario — Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for Biktarvy™ (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIKTARVY combines the potency of a novel integrase strand
